M. Puglisi

1.3k total citations · 1 hit paper
38 papers, 998 citations indexed

About

M. Puglisi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, M. Puglisi has authored 38 papers receiving a total of 998 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in M. Puglisi's work include Lung Cancer Treatments and Mutations (10 papers), Cancer Treatment and Pharmacology (7 papers) and Colorectal Cancer Treatments and Studies (6 papers). M. Puglisi is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Cancer Treatment and Pharmacology (7 papers) and Colorectal Cancer Treatments and Studies (6 papers). M. Puglisi collaborates with scholars based in Italy, United Kingdom and United States. M. Puglisi's co-authors include Sanjay Popat, Mary O’Brien, Anne S. Tsao, Joachim G.J.V. Aerts, Dariusz M. Kowalski, Kristiaan Nackaerts, S. Cedrés, Michele Maio, Anna K. Nowak and Paul Taylor and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

M. Puglisi

36 papers receiving 977 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

2017 304 citations Michele Maio, Arnaud Scherpereel et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by M. Puglisi

Since Specialization

Citations

This map shows the geographic impact of M. Puglisi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Puglisi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Puglisi more than expected).

Fields of papers citing papers by M. Puglisi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Puglisi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Puglisi. The network helps show where M. Puglisi may publish in the future.

Co-authorship network of co-authors of M. Puglisi

This figure shows the co-authorship network connecting the top 25 collaborators of M. Puglisi. A scholar is included among the top collaborators of M. Puglisi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Puglisi. M. Puglisi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	709O Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study 2024 ·Annals of Oncology ·(unknown), Yang Xiang, Kazuki Hasegawa, Giovanni Scambia, (unknown), (unknown), (unknown), Markéta Bednaříková, (unknown), Fernando Contreras Mejía, Allison B. Reiss, (unknown), June‐Yong Lee, (unknown), (unknown), Pan Liu, (unknown), M. Puglisi, (unknown), (unknown)	4
2	Gender differences in comorbidities of patients with COVID-19: An Italian local register-based analysis 2023 ·Heliyon ·Antonella Agodi, Andrea Maugeri, Giuliana Favara, Roberta Magnano San Lio, M. Puglisi, (unknown), (unknown), Martina Barchitta	4
3	L’importanza della promozione della salute mentale degli adolescenti nelle scuole 2022 ·Recenti Progressi in Medicina ·M. Puglisi, (unknown), Mirella Ruggeri	0
4	254TiP ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer 2020 ·Annals of Oncology ·Domenica Lorusso, Yang Xiang, Nicoletta Colombo, Robert L. Coleman, (unknown), Linda Duska, Kosei Hasegawa, Angélica Nogueira‐Rodrigues, David Cibula, Mansoor Raza Mirza, Benoît You, Ana Oaknin, Marie-Rose Christiaens, Çağatay Taşkıran, Jalid Sehouli, Jacob Korach, Christian Marth, Stephen J. O’Keefe, M. Puglisi, Sandro Pignata	2
5	ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer. 2020 ·Journal of Clinical Oncology ·Domenica Lorusso, Nicoletta Colombo, Robert L. Coleman, Leslie M. Randall, Linda Duska, Yang Xiang, Kosei Hasegawa, (unknown), David Cibula, Mansoor Raza Mirza, Benoît You, Ana Oaknin, Melissa Christiaens, Çağatay Taşkıran, Elena Ioana Braicu, Jacob Korach, Christian Marth, Stephen J. O’Keefe, M. Puglisi, Sandro Pignata	28
6	Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial breakdown → 2017 ·The Lancet Oncology ·Michele Maio, Arnaud Scherpereel, Luana Calabrò, Joachim G.J.V. Aerts, S. Cedrés, Alessandra Bearz, Kristiaan Nackaerts, Dean A. Fennell, Dariusz M. Kowalski, Anne S. Tsao, Paul Taylor, Federica Grosso, Scott Antonia, Anna K. Nowak, Maria Taboada, M. Puglisi, Paul K. Stockman, Hedy L. Kindler	304
7	Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions 2016 ·Oncology ·M. Puglisi, Adam Stewart, (unknown), (unknown), Suzanne Carreira, Anna Minchom, (unknown), Jaishree Bhosle, Sanjay Popat, Jonathan Ratoff, Johann S. de Bono, Timothy A. Yap, Mary O’Brien, Udai Banerji	4
8	A study of motivations and expectations of patients seen in phase 1 oncology clinics 2016 ·Cancer ·Saoirse Dolly, Eleftheria Kalaitzaki, M. Puglisi, (unknown), (unknown), (unknown), Sarah Stapleton, (unknown), Clare Peckitt, Stan B. Kaye, Juanita Lopez, Timothy A. Yap, Winette van der Graaf, Johann S. de Bono, Udai Banerji	26
9	First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014 2015 ·Clinical Cancer Research ·Bristi Basu, Emma Dean, M. Puglisi, Alastair Greystoke, Michael Ong, Wendy Burke, (unknown), Graham Bigley, Christopher J. Womack, Elizabeth A. Harrington, Stephen Green, Elisabeth Oelmann, Johann S. de Bono, Malcolm Ranson, Udai Banerji	102
10	AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines 2014 ·Lung Cancer ·M. Puglisi, P. Thavasu, Andrew N. Stewart, Johann S. de Bono, Mary O’Brien, Sanjay Popat, Jaishree Bhosle, Udai Banerji	21
11	Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience 2012 ·Annals of Oncology ·L. Rhoda Molife, Salma Alam, David Olmos, M. Puglisi, Krunal Shah, Rudolf S.N. Fehrmann, Leonardo Trani, (unknown), Johann S. de Bono, Udai Banerji, S.B. Kaye	16
12	A phase II study of 18F-fluorodeoxyglucose PET–CT in non-small cell lung cancer patients receiving erlotinib (Tarceva®); objective and symptomatic responses at 6 and 12weeks 2011 ·European Journal of Cancer ·Mary O’Brien, (unknown), Jermaine Coward, M. Puglisi, Leonardo Trani, Andrew Wotherspoon, Bhupinder Sharma, Gary Cook, S. Ashley, R. Gunapala, Sue Chua, Sanjay Popat	24
13	Phase II, open-label trial to assess the effect of continuous oral afatinib (BIBW 2992) at a daily dose of 50 mg on QTc, pharmacokinetics, and efficacy in relapsed or refractory solid tumors including brain metastases and glioblastoma that is not amenable to other therapy. 2011 ·Journal of Clinical Oncology ·Hartmut Kristeleit, M. Puglisi, Gary Middleton, David Propper, Muireann Kelleher, Leonardo Trani, (unknown), G. Wallenstein, Peter Stopfer, (unknown), M. M. Uttenreuther-Fischer, Eric H. Bent, Dennis O’Brien, James Spicer, L Rhoda Molife	5
14	A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma. 2011 ·Journal of Clinical Oncology ·Víctor Moreno, Richard D. Baird, Kinjal Shah, Bristi Basu, Nina Tunariu, Marı́a José Blanco, (unknown), (unknown), M. Puglisi, Debashis Sarker, D. Papadatos-Pastos, (unknown), Andrea Biondo, J. A. Ware, Hartmut Koeppen, (unknown), Kathryn Mazina, Johann S. de Bono	33
15	Outcomes of Patients with Metastatic Melanoma Treated with Molecularly Targeted Agents in Phase I Clinical Trials 2011 ·Oncology ·(unknown), André T. Brunetto, Sophia Frentzas, Víctor Moreno, Dionysis Papadatos-Pastos, (unknown), Leonardo Trani, M. Puglisi, L. Rhoda Molife, Udai Banerji	5
16	An analysis of the risk of toxicity associated with participation in phase 1 oncology trials of novel molecularly targeted agents (mta) at the drug development unit, royal marsden hospital 2010 ·Annals of Oncology ·(unknown), (unknown), David Olmos, (unknown), M. Puglisi, Leonardo Trani, Debashis Sarker, Montserrat Blanco, Richard D. Baird, R. Molife	5
17	Treatment options for small cell lung cancer – do we have more choice? 2010 ·British Journal of Cancer ·M. Puglisi, Saoirse Dolly, (unknown), (unknown), Sanjay Popat, Mary O’Brien	92
18	Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis 2010 ·JNCI Journal of the National Cancer Institute ·Gianluca Masi, (unknown), Fotios Loupakis, (unknown), Lorenzo Fornaro, Giacomo Giulio Baldi, Lisa Salvatore, Chiara Cremolini, I. Stasi, (unknown), Agnese Fabbri, M. Puglisi, Patrizia Trenta, Cristina Granetto, S. Chiara, Luisa Fioretto, (unknown), Lucio Crinò, M. Andreuccetti, Alfredo Falcone	137
19	Histology classification is not a predictor of clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine or gemcitabine combinations 2010 ·Lung Cancer ·Leonardo Trani, (unknown), S. Ashley, Kate Young, Amna Sheri, Ralf‐Harto Hübner, M. Puglisi, Sanjay Popat, Mary O’Brien	5
20	Use of a Modified Thromboelastograph to Evaluate Effects of Acetylcysteine on Sputum 1977 ·Respiration ·C Grassi, (unknown), (unknown), M. Puglisi	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact